Shortage of essential antimicrobials: a major challenge to global health security

Nusrat Shafiq,1 Avaneesh Kumar Pandey,1 Samir Malhotra,1 Alison Holmes,2 Marc Mendelson,3 Rohit Malpani,4 Manica Balasegaram,4 Esmita Charani3,2

ABSTRACT

The lack of access to safe and effective antimicrobials for human populations is a threat to global health security and a contributor to the emergence and spread of antimicrobial resistance (AMR). The increasingly common shortages of antimicrobials are an additional threat to the emergence of AMR. While the threat of such drug shortages is most acutely experienced in low-income and middle-income settings, their consequences impact the quality and effectiveness of antimicrobials worldwide. Furthermore, there is a need for robustly conducted studies examining the impact of these increasingly prevalent shortages on patient outcomes and on the emergence and spread of AMR. In this review, we have mapped common drivers for antimicrobial shortages and propose strategies for rethinking the regulation, supply and pricing of antimicrobials to secure their sustainable access across diverse healthcare systems and to help minimise the unintended consequences of weak and ineffective supply chains. Greater government involvement in antimicrobial manufacture and supply is essential to ensure no one is left behind. Dedicated demand systems need to be developed for antimicrobials which take into consideration evolving AMR patterns, burden of diseases, pandemic events and supply and demand issues and facilitate implementation of strategies to address them. Interventions, ranging from advocacy and forecasting to public–private collaborations, new economic models and international consortia working across countries and supply chains, will help assure access to safe and effective antimicrobials to all populations around the globe and ensure that shortages no longer contribute to AMR.

INTRODUCTION

Sustainable availability and supply of antimicrobials is under constant threat both locally and globally. Antimicrobial shortages are increasingly hindering timely access to effective therapies. The lack of access to antimicrobials is a driver of excess mortality, particularly in low-income and middle-income countries (LMICs).1 The list of affected antimicrobials includes penicillin, cefazolin,2,3 clofazamine,1 dapsone,1 rifabutin,6 piperacillin–tazobactam, ceftolozane–tazobactam7 and clavulanic acid.8 The consequences of these shortages are not well documented in literature. Besides a direct effect on healthcare outcomes, shortages of antimicrobials pose an additional public health threat. Resorting to alternative antimicrobials due to the unavailability of the most appropriate agent (eg, as in the case of piperacillin–tazobactam and cefazolin) may lead to compromised outcomes including suboptimal use of antibiotics.9,10 The more recent shortages and their cause and consequences are summarised in table 1. The economic consequences of such shortages are immense, with a WHO report estimating the economic cost of the shortage of just one antimicrobial to be €20–30 million.11 Though not mentioned in the report, the economic loss could be a result of many factors including using higher cost antibiotics, relying on suboptimal therapeutic options leading to more complications and creation of market opportunities for substandard and falsified alternatives.12

Selecting suboptimal antibiotics can result in drug-resistant infections and contribute

Summary box

- Shortages of antimicrobials are an increasingly common occurrence worldwide. Such shortages are a threat to the emergence and spread of antimicrobial resistance, and more importantly a threat to access to effective therapies.
- While the drivers for shortages vary, the consequences impact all countries. Globally, there is no consensus in policy or strategy for forecasting or managing such shortages.
- Mapping the most common drivers for antimicrobial drug shortages, we propose potential strategies for rethinking the regulation, supply and pricing of antimicrobials to secure their sustainable access across diverse healthcare systems and help minimise the unintended consequences of weak and ineffective supply chains.
- Identifying a global solution with regional focus to the prevailing antimicrobial supply issues will contribute to global antimicrobial security and support more equitable access to antimicrobial therapies for populations in different countries.
AMR is recognised as a global public health challenge with an estimated annual mortality of 700,000 attributed to the burden of antimicrobial resistance (AMR). AMR is an impediment to achieving the Sustainable Development Goals; insufficient action could push a further 24 million people into extreme poverty by 2030.15

Table 1  Summarising some of the key antimicrobial shortages worldwide in the last 10 years and the causes and consequences of these shortages

<table>
<thead>
<tr>
<th>Drug shortage</th>
<th>Timeline</th>
<th>Regions affected*</th>
<th>Cause</th>
<th>Consequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amoxicillin</td>
<td>2018–2021</td>
<td>Canada, India</td>
<td>Suspension by manufacturer, disruption in supply of API due to pandemic, possible increase interest in investment in amoxicillin-clavulanic acid.</td>
<td>For community acquired infections, one may be compelled to use amoxicillin-clavulanic acid which is a broad-spectrum antimicrobial. The shortage of the paediatric formulation is particularly important.</td>
</tr>
<tr>
<td>Amphotericin B</td>
<td>2021</td>
<td>India</td>
<td>Surge in demand as a first line treatment for mucormycosis.</td>
<td>Using alternative agents with no or sparse clinical trial evidence of efficacy, for example, posaconazole. Potential for treatment failure and increased morbidity and mortality.</td>
</tr>
<tr>
<td>Cefazolin</td>
<td>2016 onwards</td>
<td>Japan, India</td>
<td>Decreased production, increased demand, price caps.</td>
<td>Cefazolin is a major drug recommended for surgical prophylaxis and for treatment of staphylococcal infections. Lack of its availability may compel use of alternatives which may not be as effective and could have broader spectrum, adversely affecting AMR.</td>
</tr>
<tr>
<td>Cefazolin</td>
<td>2016 onwards</td>
<td>USA, Europe, Canada, India</td>
<td>Disruption of manufacturing due to declining market returns.</td>
<td>Cloxacillin is an important drug for methicillin susceptible staphylococcal aureus infection, compels use of alternative agents such as amoxicillin-clavulanic acid or vancomycin leading to worse outcomes.</td>
</tr>
<tr>
<td>Cotrimoxazole</td>
<td>2018 onwards</td>
<td>Africa, Australia</td>
<td>Suspension of production by manufacturing companies.</td>
<td>Cotrimoxazole is an important drug for community acquired infections and some hospital acquired infections. It is also an important drug for prophylaxis and treatment of opportunistic infections in immunocompromised states such as HIV infections.</td>
</tr>
<tr>
<td>Penicillin G</td>
<td>2015– ongoing</td>
<td>39 countries</td>
<td>Only four companies produce the active pharmaceutical ingredient and due to lack of profitability production levels were kept low. Fragmented production process, including lack of regulation and quality standards in factories producing raw materials.</td>
<td>Restricts treatment options for syphilis and rheumatic heart disease—conditions disproportionately affecting low-income and middle-income countries. Increased risk of maternal to foetal transmission of syphilis. Increased costs of therapy as substitute therapies more expensive.</td>
</tr>
<tr>
<td>Piperacillin–tazobactam</td>
<td>2017</td>
<td>Worldwide</td>
<td>Explosion at the sole factory in China supplying the active pharmaceutical ingredient.</td>
<td>Use of more broad-spectrum agents such as carbapenems. Increased use of cephalosporins with increasing risk of c-difficile infection.</td>
</tr>
<tr>
<td>Dapsone</td>
<td>2017</td>
<td>Korea</td>
<td>Shortage of raw material and rising costs.</td>
<td>Compromises the management of both leprosy and several other dermatological conditions for which dapsone is often used.</td>
</tr>
<tr>
<td>TB medication shortages</td>
<td>2011</td>
<td>UK, South Africa, India</td>
<td>Manufacture and supply chain issues for various drugs including ethionamide, clofazimine, streptomycin, rifabutin, protionamide, capreomycin.</td>
<td>Interruptions to TB therapy regimens including for MDR-TB therapy. Using unlicensed, variable-strength and unlicensed suspensions for paediatric dosing.</td>
</tr>
</tbody>
</table>

*The mentioned countries/regions are highlighted because they have reported shortages. AMR, antimicrobial resistance; API, active pharmaceutical ingredients; MDR-TB, multidrug-resistant tuberculosis; TB, tuberculosis.
Data on the availability of medicines are patchy and limited. The WHO has conducted a survey of availability of selected generic medicines, for which there are data from only 30 countries. The data for most of the countries are from one survey on the availability of a specific list of medicines in the country using a sample of medicine dispensing units. The available data report that the median percent availability (calculated from medicine dispensing outlets in at least four geographic or administrative areas) of most drugs seldom reach the global target of 80%. The limited data, which are available on the extent and consequence of such shortages, indicate that antimicrobial shortages are an increasingly global problem with many high-income countries (HICs) also affected.

**REASONS FOR ANTIMICROBIAL SHORTAGES**

Across the development, distribution and use pathway, shortages can be attributed to: (a) inefficient and fragmented supply chains issues, (b) poorly functioning systems of financing and drug pricing environment and (c) issues related to policy and regulatory processes. Within these broadly defined categories, a more specific classification of the causes of shortages includes the following: (1) a lack of commercial incentive and market; (2) unavailable or inefficient forecasting systems; (3) single source or gaps in active pharmaceutical ingredients (APIs) and other essential materials; (4) limited quality manufacturing of source materials; (5) complex and fragmented procurement of products; (6) regulatory challenges and (7) inadequate constitutive recognition of access to essential medicines (figure 1). All these reasons contribute to commercial non-viability, discouraging pharmaceutical companies from investing in manufacture and supply of antimicrobials. The causes of shortages are often interrelated and lead to adverse unintended consequences. For example, the growing prevalence of betalactamase-producing Gram-negative bacteria has increased the availability of combination beta-lactamase inhibitors. Many of these combination agents lack a robust evidence-base for their use, and they are often used inappropriately, especially where single agent preparations are not available. Practitioners in India, for instance, have difficulty in getting amoxicillin, while amoxicillin-clavulanic acid is easily available.

**Inefficient and fragmented supply chains compounded by weak forecasting systems**

Global antimicrobial supply chains are inefficient and fragmented. Such fragmentation of supply systems hinders the ability to forecast and mitigate against shortages. Some segments of the antimicrobial supply chain may have multiple stakeholders and companies with vested interests, while other segments of the supply chain may have very few players and thus may be highly concentrated. India and China are the major suppliers of API for antimicrobials, while manufacturers are more widely distributed. A disruption at any point in the API supply chain can bring the entire process to a halt. In 2016, a fire in the manufacturing unit of the API for piperacillin–tazobactam disrupted its global supply.

The fragility of global supply chains is exacerbated by weak forecasting systems. Although the importance of forecasting systems in maintaining supply chains for antibiotics has been highlighted, the demand forecasting systems continue to be inaccurate. More importantly, in developing countries, scarcely available and poorly functioning forecasting systems contribute to the problem of disrupted supply chains. Additionally, the absence of pooled procurement mechanisms can both assure

**Figure 1** The reasons for antimicrobial shortages across the development, distribution and use pathway.
demand, and proactively represent the interests of end users to stabilise production and supply.28 Pooled institutional procurement for antimicrobials is either absent or underdeveloped, except for the global drug facility (GDF), which is hosted by the Stop TB Partnership, and which purchases antimicrobials for TB and distributes them to at least 130 countries, including HICs, for example, Australia.29 However, there are circumstances when even a pooled procurement facility such as GDF cannot guarantee timely availability of medicines.

Strategic partnerships and alliances, of which there are many in global health for different diseases (such as leprosy, river blindness or leishmaniasis) are also vulnerable to fragile supply chains. However, even for such partnerships and alliances, if a company stops manufacturing or supplying the drugs critical to a partnership or alliance, citing, for example, market-related issues, then the recipients in a partnership suffer. One example is clofazimine, a drug used for the treatment of multidrug resistant TB, originally provided by Abbott. Subsequently, Abbott India informed the National Pharmaceutical Pricing Authority (NPPA) that the company was unable to continue with production of clofazimine citing nonavailability of raw materials. In this instance, active intervention from the drug regulators was needed to rectify the situation.30

Poorly functioning system of financing and drug pricing environment

Both patented and off-patent antimicrobials are affected by the financing and drug pricing environment. For pharmaceutical companies, the opportunity cost of investing in antimicrobials and the net present value compared with other therapeutic areas such as cancer and chronic cardiovascular disorders discourages commercial research and development investments.31 This has created an environment where innovation and technology and early translational research in the field of antimicrobials frequently springs from public sector funding, philanthropic agencies and institutions, either through direct investments in companies and trials or through indirect funding of product development partnerships such as the TB alliance. If successful throughout the initial discovery phase, investigational compounds and other medical technologies are ‘handed over’ or ‘spun out’ to private enterprises whose efforts in further development, marketing and distribution are driven by market considerations.32

While significant public and philanthropic funding drives the drug development cycle, manufacturing and a company’s decision to maintain adequate supply, often depends on the product price. Low prices of antimicrobials can be a direct cause of a shortage. For example, in India, the availability of certain antimicrobials was negatively affected when antimicrobials listed on the national essential medicines list (EML) were placed under the ambit of the Drugs and Price Control Order (DPCO) 2013, capping the maximum market price for drugs in the national EML.33 EMLs, first produced by the WHO, are intended to be a minimum list of medicines that satisfy basic requirements of a healthcare system.34 Since the first EML issued by WHO, countries have developed national EMLs reflecting the healthcare needs of their populations. The purpose of the DPCO was to cap the maximum market price for drugs on EML and ensure essential medicines remain accessible to all. However, an unintended consequence was that the manufacture and availability of certain drugs were threatened as pharmaceutical companies possibly determined profitability was inadequate to sustain manufacturing.2

Benzylenicillin, a first-choice treatment for prevention of mother to child transmission of syphilis as well as the management of rheumatic heart disease, is an example of an antimicrobial that though medically essential, is not a financially viable product. The manufacture of the injectable form requires sterile conditions, which means investment in manufacturing infrastructure. However, the finished product has a very low market price (US$ 0.11–0.2 per unit dose, depending on the dosage). Worldwide, only four companies manufacture the API for penicillin, and due to low profit margins, manufacturing is now downsized to a minimum.35

In contrast to the conditions of financing and the drug pricing environment, intellectual property laws and regulations that create market monopolies can suppress demand when prices are too high. The price structure of patented new agents that come to market often prohibit their use in LMICs. Companies frequently do not make such new products available in LMICs due to an anticipated lack of financial return.36 Whether decreased initial availability impacts antimicrobial shortages needs to be studied.

Issues related to policy and regulatory processes

It is important to also reflect on the central role that governments have in addressing the problem of shortages. Ensuring availability and access to essential services and essential goods remain the responsibility of governments and should be required under a country’s constitution or equivalent. And yet, while the provision of healthcare services is regarded as an ‘essential service’, there is no systematic tracking of whether and how countries ensure access to essential medicines.37 This is important because sustained availability of essential medicines is integral to access to antimicrobials, at least those which are included on the EML. Until 2016, only 22 National Constitutions across the globe recognised governments’ responsibility towards protecting the right to access and/or availability and quality of medicines.37 A constitutional mandate to uphold a right to access to medicines would require governments to regulate, forecast and ensure that supply chain management does not undermine access to affordable, quality-assured antimicrobials and establish mechanisms for accountability for antimicrobial shortages.

Another problem is that shortages create a void in the market. Antibiotic demand does not diminish in times of

antibiotic shortages. The gap in the market is at risk of being exploited by substandard, counterfeit and falsified medicines. In countries where legislation around quality assurance of antibiotics is not enforced or strictly regulated, the infiltration of such products into the market is made easier. Such a situation may be particularly prevalent in pluralistic health systems where the population supplement their healthcare needs through out-of-pocket expenses and choose between private and public care.38

STRATEGIES AND TACTICS TO ADDRESS ANTIMICROBIAL SHORTAGES

Addressing shortages will require different strategies to both anticipate and respond to this on-going challenge. In the section below, we present the key strategies together with enabling tactics to foster appropriate responses to acute and chronic shortages.

Organised, coordinated, and strengthened forecasting

Economically viable strategies should be explored for addressing existing challenges in manufacture and supply. An economically viable strategy requires accurate, dedicated and trustworthy forecasting which itself is based on collaboration between public sector organisations, governments and civil society.39 Systems for collating sales and purchase data of antimicrobials, future requirements of antimicrobials and available buffer stocks, are lacking in several regions. Beyond establishing these systems, substantial training is required to ensure such a system is viable and sustainable. Effective forecasting requires strategies for procurement and for measurement. Developing procurement partnerships across health systems, countries and regions will enable greater leverage to exploit opportunities for optimising acquisition of antimicrobial agents.

Building forecasting capacity, particularly in LMICs requires an understanding of the market dynamics, both formal and informal and the drivers for antimicrobial use and demand.26 40 Improved data gathering, managing and sharing is essential in benchmarking for medication use, budgetary planning, as well as tracking infectious diseases epidemiology and AMR. We propose that dedicated demand forecasting and preparedness systems for antimicrobials are developed, building on existing surveillance systems and investing in developing sustainable surveillance where it is lacking. Cooperation and appropriate data sharing are essential with and across existing platforms like WHO’s Global Antimicrobial Resistance Surveillance System (GLASS), World Organisation for Animal Health (OIE) surveillance network for AMR in animals and from data on antimicrobial sales. Capacity needs to be built for surveillance across private organisations. Any issue related to AMR, including that shortage of essential antimicrobials would necessarily need to be planned within a ‘One Health’ framework at the outset or in a staged manner. The planning and implementation for running such a system is daunting and would require intersectoral cooperation and commitment and support of national governments. Therefore, political commitment is critical to the strategy of forecasting which should also incorporate pandemic preparedness. Important challenges such as international power disequilibrium overshadowing the interests of LMICs, regional politics and conflict zones, all would need to be simultaneously addressed with added safeguards.

Subscription models

While demand for antimicrobials has grown, the number of actors involved in manufacturing and distribution has decreased. Several AMR stakeholders have highlighted this issue and suggested options such as fixed yearly payment for guaranteed supply, incentives to maintain or expand production and tenders that ensure allocation to several suppliers to sustain a healthy market.21 The ‘Netflix model’ adopted in Australia to procure Direct Acting Antivirals (DAA) to treat Hepatitis C is an example of such a model, although its use was tied more closely to assuring affordability as opposed to safeguarding supply.41 The Australian model was built on a form of delinkage, or decoupling funding of or payment for research and development from the end-product price. To do so, the government paid a lump-sum that estimated total demand for DAs for patients with Hepatitis C infection. In AMR, delinkage can focus on delinking payment from sales revenue (volume and prices) to discourage inappropriate use and assure affordability.42 Such a model could be deployed to assure adequate supply based on forecasted need of an antibiotic over a defined period, while ensuring a manufacturer’s sales revenue is tied neither to the price paid nor the volumes sold.43

More recently, countries like the UK and Sweden have started to explore alternative payment models for both new and older antibiotics. Such models need to be explored and piloted by LMICs.43 Voluntary licensing

Voluntary licensing refers to the practice by ‘patent holding pharmaceutical corporations (licensors) to set out the terms under which a generic version of a patented medicine can enter the market from alternative suppliers (licensees)’.44 This practice can have a positive public health impact and enable greater access to generic medicines in LMICs if patent holders issue appropriate voluntary licenses, with technology transfer (where appropriate). One example of a voluntary license contributing to public health objectives is the National Program on Control and Prevention of viral hepatitis in India, which facilitated mechanisms for health systems within each State to procure affordable, generic versions of DAs for Hepatitis C (which otherwise are patented), providing it free of charge to patients in government-funded clinics. These medicines were manufactured under voluntary licenses.45 The production of DAs under voluntary license in India provided greater access to these medicines in other LMICs through inclusion
in the territory of the voluntary license or because the patent holder had not sought patent protection for those DAAs in certain countries. By contrast, the unwillingness of patent holders for new anti-TB medicines bedaquiline and delamanid to negotiate voluntary licenses with generics manufacturers or entities such as the Medicines Patent Pool has translated into on-going challenges with affordability, availability and uptake of these medicines to treat drug-resistant TB. These drugs are made available in certain parts of the world through their compassionate use programme or conditional access for programmatic management for multidrug resistant TB. While availability of drugs through compassionate use programmes ensures availability of medicines, dependency on the manufacturer continues to remain. Another case in point are the few voluntary licenses for COVID-19 vaccines and therapeutics. These examples highlight that while voluntary licensing can be a useful tool to ensure early access to antimicrobials in countries with a high burden of infectious diseases, it is essential that such licenses have appropriate terms and conditions and are backed by strategies for quality assurance. Appropriate voluntary licenses can be assured through contractual obligations introduced by public and philanthropic funders of research and development, or by governments (that are excluded from or negatively impacted by voluntary licenses for antimicrobials) exercising public health safeguards enshrined in global trade agreements.

Facilitating regulatory processes

Strategies targeted at improving regulatory approval processes could be instrumental in making new therapeutics available without a significant lag period between first introduction to market and subsequent product launches in different countries. Collaborative regulatory approval processes, supported by WHO such as the prequalification programme and the collaborative registration system have been instrumental in ensuring timely access, positively impacting public health and cost savings. Other approaches such as deployment of emergency use authorisation (EUA) and compassionate use, can also facilitate early availability of new antimicrobials. EUA has enabled companies to supply their products to countries during the current pandemic and facilitated access to drugs in certain areas of India to address multidrug resistant TB. The process of WHO prequalification programme can be strengthened to enable quicker access to finished pharmaceutical products and API particularly in LMICs. Certification of quality for vaccines by WHO under its EUA procedure has been instrumental in accelerating access to quality vaccines to large parts of the world. However, EUA should primarily be seen as a short-term tool prior to introduction of harmonised and collaborative regulatory processes and should not undermine requirements for companies to conduct full clinical trials and pharmacovigilance to ensure safety and efficacy.

Importantly, the need for inclusion of access to essential medicines either independently or within the framework of right to health in national constitutions needs considerable deliberation. A good starting point would be to make a repository of existing national legislations and corresponding enabling regulations and policies about access to essential medicines including essential antimicrobials, as has been previously suggested. A model legislation with provisions for modification in accordance with legal frameworks in which individual countries function would be useful. International cooperation to encourage adoption of such legislation in all countries would be required.

Local drug manufacturing

The local manufacture of drugs, often viewed as an exceptional measure to expand access, has gained traction as a means to assure supply and access to medicines in response to the shortages linked to the COVID-19 pandemic. Government-funded local or regional manufacturing hubs have been mooted and more recently piloted for mRNA COVID-19 vaccine manufacture. A portfolio of strategic antimicrobials at risk of shortages could be targeted for manufacturing and supply through such regional hubs. Furthermore, these regional hubs could be developed to facilitate the prioritisation and manufacturing of API, where needed. Expanding local and regional production hubs to manufacture and supply APIs, could shift the current dominance of API production from China to more globally dispersed market hubs. This would prevent monopolisation of manufacturing capacities and could also introduce competitive pricing of API, which would be beneficial in reducing cost of goods. The production hub model, however, may not be the solution for sustainable access to less profitable antimicrobials whose profit margins may be a disincentive to large-scale manufacture. Resilient models which are not vulnerable to supply chain disruptions could be more useful in achieving global health and antimicrobial security. Important elements of such models include balanced geographic distribution of production units, multiple players at each stage of manufacturing and systems to facilitate forecasting. While HICs have already started addressing the issue in a more organised manner, there is little evidence of deliberate and strategic planning within or across LMICs.

Such strategies need to be facilitated through tactical engagement and collaboration with key stakeholders including policy makers, civil society and the public and private sector. Three key tactics are needed: (i) establishing international consortia; (ii) public–private partnerships for antimicrobial manufacture and (iii) building capacity for public sector manufacture of antimicrobials.

Establishing international consortia to forecast, manage and respond to the antimicrobial supply and availability issues

One means to address the growing problems of shortages of antimicrobials would be to create global and regional
consortia with the participation of different stakeholders. This can be backed by an international legal framework to address AMR as has been previously suggested.57 Figure 2 outlines what such a consortium might look like. The legitimacy of such an international consortium would be grounded in the right to healthcare and the progressive integration of access to medicines within the framework of constitutions of nations. Successful collaboration with different stakeholders within the consortium may be able to influence international regulations and trade rules, facilitating more effective and sustainable movement of essential pharmaceutical components. Yet even if international consortia intend to encourage collaboration among governments and between the public and private sector on an equitable basis, such entities need to avoid replicating or exacerbating existing imbalances and need to allow individual governments, the flexibility to address supply and access challenges independently when required. Importantly, governance structures need to be balanced between Northern and Southern countries (with a role for civil society and independent experts), via transparent decision-making and reporting to facilitate accountability and by encouraging financial contributions by all participating governments according to ability to pay.

Public–private partnerships for antimicrobial manufacture
Production and supply of medicines can be located exclusively within the public or private sector. We discuss several ways in which public sector manufacture of medicines can be deployed and strengthened. Yet such public sector production may not be adequate for all medicines and vaccines of public health importance, especially as some governments may not wish to assume responsibility for public sector manufacture. Partnering with or regulating the private sector, with appropriate regulation, can help the public sector fill gaps or address other unmet needs.

One reason public sector production may not be sufficient is that manufacturing can be a complex endeavour that may be best accomplished through collaboration between the public and private sectors. Public–private collaboration in the pharmaceutical field has already achieved significant outcomes on an accelerated timetable, such as the development and manufacture of new COVID-19 vaccines and therapeutics, although such outcomes may not always be equitable.58

The manufacture and timely supply of antimicrobials may involve utilising a mix of approaches including through public production, oversight of the private sector or through public–private partnerships. Ultimately, it can only be successful if governments are responsible for ensuring supply.

Different models from other sectors should be evaluated for learning, for example, partnerships which encourage innovation while successfully working with government and research organisations. A good learning, for example, would be that of manufacturing capacities for space programmes which require great deal of sophistication and complexity and successful programme modelled on public–private collaboration exists.59

Dedicated facilities for production of antimicrobials and/or vaccines facing shortages or named in EMLs
An internet search for public sector units (units primarily funded by government with or without support from other international organisation) producing finished pharmaceutical products of antimicrobials indicates that a substantial percentage are situated in India.60 Some key examples are Hindustan Antibiotics,61 Rajasthan

---

**Figure 2** A proposed consortium for assuring access to antimicrobials and vaccines. API, active pharmaceutical ingredients; NGOs, non-governmental organisations; PSU, Public Sector Undertakings.
Drugs and Pharmaceuticals, Jaipur,\textsuperscript{62} Bengal Chemi-
cals and Pharmaceuticals, Kolkata,\textsuperscript{63} Indian Drugs and Phar-
maceuticals\textsuperscript{64} and the Central Research Institute,
Kasauli.\textsuperscript{55} Examples from across the globe include
Institute Pasteur Tunis,\textsuperscript{66} Drug Technology Institute,
Fiocruz\textsuperscript{67} and Staatens Serum Institute.\textsuperscript{68} Fiocruz,
which is affiliated with the Oswaldo Cruz foundation in Brazil,
contributes to nearly 40\% of the Brazilian government’s
drug procurement. Such public sector units both manu-
facture small molecules, and are important facilities
for vaccine, sera and antibody production. The major
Chinese companies now dominating international API
manufacturing originated as publicly owned units in the
1950s. In recent years, many of these companies are oper-
ating as private entities.\textsuperscript{59} These institutes have existed for
several decades and have benefited from investments
and contributions by intergovernmental agencies such as
WHO and UNICEF (Hindustan Antibiotics Limited).
The infrastructure and trained manpower of such manu-
facturing units can augment production and assure the
availability of antimicrobials. We suggest that building on
such existing investments and infrastructure, a dialogue
should be initiated to strengthen the capacities of existing
units, invest in more units, improve the efficiency of the
workforce and ensure a constant supply of medicines,
especially for conditions of public health importance.
Importantly, such units can be useful for manufacturing
of important drugs requiring only small volumes and
drugs that need dedicated facilities like beta-lactams.

Such dedicated facilities do not have to reside solely
in the public sector. Collaboration with private manu-
facturers and innovator companies can be central to
developing and operating such a facility, as well as for
technology and knowledge transfer and ensuring second
site production for low volume old and new antibiotics.
Where the private sector no longer wishes to produce
commercially non-viable products, such collaborations,
with technology transfer to a public sector facility, can be
a viable exit strategy for such products. A good example
of such an initiative is that of CivicaRx in the USA which
is dedicated to manufacturing and supplying low-cost
generics and drugs on EML.\textsuperscript{69} Although it is a private
enterprise, the company is partnering with governmental
and regulatory agencies to enable the focus of the
company.

CONCLUSION
Shortages of medicines, especially antimicrobials, are a
threat to global health security and need to be treated
with the same urgency as food and energy shortages.
Not only do antimicrobial drug shortages affect access,
but they also contribute to inappropriate antimicrobial
use and drive AMR. To build robust systems capable of
forecasting, mitigating against and responding to anti-
microbial shortages, improved government collaboration
and participation is essential. Sustainable preparedness
against the threat of drug shortages and their unintended
consequences, through policy and strategy will ensure that
no one is left behind. Private sector, non-governmental
organisations, community groups and societies also have
an important role to play in meeting strategic goals and
objectives tackling antimicrobial shortages worldwide.
To ensure that antimicrobial shortages no longer pose
a threat to the emergence of AMR and global health
security, a multimodal strategy is needed, which includes
interventions ranging from advocacy and forecasting
to public–private collaborations, new economic models
and the proposed international consortia. Only through
global partnership and collaboration will we be able to
address the issues that undermine antimicrobial supply
and access.

Twitter Esmita Charani @e_charani
Acknowledgements EC, MM and AH acknowledge funding from the Economic
and Social Research Council (ESRC) and the National Institute for Health
Research ASPIRES project (Antibiotic use across Surgical Pathways: Investigating,
Redesigning and Evaluating Systems) (https://www.imperial.ac.uk/arc/aspires/).
ASPIRES aims to address antimicrobial resistance and improve clinical outcomes
optimising antibiotic usage along surgical pathways. The support of ESRC as
part of the Antimicrobial Cross Council initiative supported by the seven UK
research councils, and the support of the Global Challenges Research Fund, is
gratefully acknowledged. Chakraborty Muthsara, PhD student in the Department
of Pharmacology, Postgraduate Institute of Medical Education and Research prepared
the first draft offigure 2 with input from the coauthors.
Contributors NS, EC and SM conceived of and drafted the paper. MB and RM
moderated on the first draft. MB, RM, AK, AH and MM contributed to framing of
key points. All authors contributed to editing and finalising the paper. EC as the
guarantor accepts full responsibility for the work and overall content.
Funding EC was funded by the Academy of Medical Sciences Hamled Foundation
UK-India AMR Visiting Professorship Award.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data relevant to the study are included in the
article.
Open access This is an open access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited, appropriate credit is given, any changes made indicated, and the
use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
ORCID iD
Esmita Charani http://orcid.org/0000-0002-5938-1202

REFERENCES
access to achieve appropriate human antimicrobial use in low-
2 Kakkar AK, Shafiq N, Malhotra S. Ensuring access to ‘access’
antibiotics: an imminent consideration for sustainable antimicro-
3 Kakkar AK, Shafiq N, Malhotra S. Cefazolin shortages in the
developing world: the same, but different too. \textit{Clin Infect Dis}
4 Tuberculosis drug shortage alert - Telegraph India. Available: https://
www.telegraphindia.com/health/tuberculosis-drug-shortage-alert/
cid/1748324 [Accessed 6 May 2021].
5 2 orphan drugs find manufacturers in Korea. Korea biomedical


17 Beraud G. Shortages without frontiers: antimicrobial drug and vaccine shortages impact far beyond the individual! *Front Med* 2021;8:593712.


50 Perheodo K, Alexander NV, Hogerzel HV. Legislating for universal access to medicines: a rights-based cross-national


